TuHURA Biosciences’ (HURA) “Sell (E+)” Rating Reaffirmed at Weiss Ratings

TuHURA Biosciences (NASDAQ:HURA)‘s stock had its “sell (e+)” rating reissued by stock analysts at Weiss Ratings in a research note issued on Wednesday,Weiss Ratings reports.

HURA has been the topic of several other reports. Wall Street Zen upgraded shares of TuHURA Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, September 20th. Brookline Capital Management upgraded shares of TuHURA Biosciences to a “strong-buy” rating in a report on Monday, June 23rd. Two investment analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Buy” and an average target price of $12.67.

TuHURA Biosciences Trading Up 4.4%

HURA opened at $2.61 on Wednesday. The firm’s fifty day moving average is $2.65 and its two-hundred day moving average is $3.01. TuHURA Biosciences has a twelve month low of $1.80 and a twelve month high of $8.40.

TuHURA Biosciences (NASDAQ:HURA) last posted its earnings results on Thursday, August 14th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.07).

Institutional Investors Weigh In On TuHURA Biosciences

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of TuHURA Biosciences during the second quarter worth $31,000. Merck & Co. Inc. bought a new position in TuHURA Biosciences in the second quarter valued at $31,000. Marshall Wace LLP bought a new position in TuHURA Biosciences in the second quarter valued at $79,000. Invesco Ltd. bought a new position in TuHURA Biosciences in the second quarter valued at $30,000. Finally, New York State Common Retirement Fund bought a new position in TuHURA Biosciences in the second quarter valued at $97,000. 0.62% of the stock is currently owned by institutional investors and hedge funds.

About TuHURA Biosciences

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.